With sales exceeding US$146 billion over the past decade, U.S. pharmaceutical giant Merck’s Keytruda has become the ...

Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory ...

Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...

A new round of Medicare drug price negotiations shows the impact of the Inflation Reduction Act while exposing an ongoing political fight over who deserves credit for lowering drug costs. The Trump ...

As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of ...

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

Celltrion has unveiled its 'growth blueprint,' focusing on expanding its manufacturing facility in the United States, making ...

Merck’s MRK strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

Promega has scored an FDA green light for its microsatellite instability testing technology as a companion diagnostic for Merck and Eisai’s Keytruda-Lenvima combination for patients with advanced ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of ...